Expectations trend
FY2027 · fiscal year ending 2027-09-30 · fmp
CEL-SCI Corp (CVM)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$1.37-0.72%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CVM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduction in net loss per share | A primary condition in CEL-SCI Corp's published investment case. The stated target is EPS improves from -$4.16 in 2026 to better than -$0.92 in 2027. | Broken | EPS does not improve or worsens beyond -$0.92 in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-09-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making development-stage company, not an established earnings compounder. The multi-year view is on watch because the partnership is early and there is not yet evidence of its financial impact.
The snapshot provides no valuation measure or specific evidence about market expectations, so whether CVM is cheap or expensive versus peers cannot be assessed. It does show recent upward price reaction, but that alone does not establish what the market assumes about Multikine or the partnership.
Near-term results are likely to remain pressured: quarterly net losses and negative operating cash flow have stayed substantial, while equity offerings have helped fund development and corporate needs. The Amarox partnership could support commercialization in Saudi Arabia and potentially the GCC, but revenue sharing depends on SFDA approval and no financial impact is reported yet. Near-term miss risk is elevated, and recent financial performance remains below the industry cohort.
Over the multi-year horizon, the thesis hinges on progress toward SFDA approval and whether the Amarox partnership can produce meaningful revenue. It also depends on whether CEL-SCI can manage ongoing cash burn and funding needs. In the near term, a weaker jobs trend could weigh on cyclical names, while results and guidance from healthcare bellwethers may affect the sector backdrop.
CVM’s multi-year view is uncertain: the partnership offers a possible commercialization path, but persistent losses, negative operating cash flow, and funding needs remain central risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company raised $7.2 million in an equity offering in 2026-Q2 to support operations. |
| Intact |
| Equity offering raises less than $7.2 million or fails to close by 2026-Q2 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Progress in strategic partnership with Amarox for Multikine commercialization | CEL-SCI formed a strategic partnership with Amarox to commercialize Multikine in Saudi Arabia and GCC. | Improving | Partnership fails to advance regulatory or marketing milestones by end 2026 | Qualitative progress confirmed vs End-2026 target May 2026 Amarox agreement for Multikine commercialization; June 2026 confirmatory study start for head and neck cancer. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-6.38 → $-6.38 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-07-25 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-07-26 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-07-27 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-07-28 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-07-29 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-07-30 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-07-31 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-01 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-02 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-03 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-04 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-05 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-06 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-07 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-08 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-09 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-10 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-11 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-12 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-13 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-14 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-15 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-16 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-17 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-18 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-19 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-20 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-21 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-22 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-23 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-24 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-25 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-26 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-27 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-28 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-29 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-30 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-08-31 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-01 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-02 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-03 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-04 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-05 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-06 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-07 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-08 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-09 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-10 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-11 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-12 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-13 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-14 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-15 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-16 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-17 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-18 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-19 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-20 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-21 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-22 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-23 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-24 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-25 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-26 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-27 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-28 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-29 | $-6.38 | $5,972,000 | 1 / 1 |
| 2026-09-30 | $-6.38 | $5,972,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.